Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

Novartis and NHS launch mobile eye unit in UK

Novartis and NHS launch mobile eye unit in UK Novartis' interests in the area lie in Lucentis (ranibizumab), which is recommended by the National Institute for Health and Care Excellence (NICE) to treat wet AMD among other eye conditions. ... Bayer's drug is recommended as a monthly treatment for

Bayer files eye drug Eylea for new use in EU

Bayer files eye drug Eylea for new use in EU Registration would also help Bayer in its tussle for market share in the macular disease area with Novartis' Lucentis (ranibizumab), which is already approved for BRVO but only in patients who

Novartis licenses Ophthotech eye drug in $1bn deal

Novartis licenses Ophthotech eye drug in $1bn deal Novartis already sells anti-VEGF (vascular endothelial growth factor) drug Lucentis (ranibizumab) for wet AMD - as well as other indications such as pathological myopia and macular oedema - and achieved sales of ... Competition in the AMD sector is on

NICE backs new use for Bayer’s Eylea

NICE backs new use for Bayer’s Eylea Will go up against Novartis’ Lucentis in treatment of macular oedema in UK. ... Eylea is already available on the NHS to treat wet age-related macular degeneratio n (AMD), a condition for which Lucentis is also approved.

Interview: Beate Wieseler, IQWIG

Interview: Beate Wieseler, IQWIG effectiveness over Novartis' Lucentis (ranibizumab) in the treatment of wet age-related macular degeneration (AMD).

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics